Accelerate Diagnostics Inc
Most Recent
What Analysts Recommend for Accelerate Diagnostics and Peers
Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.
What Are Accelerate Diagnostics’ Key Strengths?
In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.
Does Accelerate Diagnostics’ Financial Performance Bode Well?
The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.
What’s the Competitive Landscape for Accelerate Diagnostics?
Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).
What’s the Potential Market for Accelerate Diagnostics’ Products?
Accelerate Diagnostics’ (AXDX) pheno system utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests.
